Evidence map›Paper›PMID 40405479›Full record

ArticleArchiv der Pharmazie2025

Evernic Acid: A Low-Toxic and Selective Alternative to Chemotherapeutic Agents in the Treatment of Ovarian Cancer.

Mine Ensoy, Damla Nur Parıltı, Ayşe Hale Alkan, Kübra Nur Kaplan İlhan, Pelin Mutlu, Bala Gür Dedeoğlu, Demet Cansaran-Duman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mine EnsoyBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Damla Nur ParıltıBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Ayşe Hale AlkanBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Kübra Nur Kaplan İlhanBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Pelin MutluBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Bala Gür DedeoğluBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.
Demet Cansaran-DumanBiotechnology Institute, Ankara University, Keçiören, Ankara, Türkiye.ORCID https://orcid.org/0000-0001-5662-2333

Funding

This study was funded by the Ankara University.
6 · The paper itself

Abstract

Evernic acid (EA) has emerged as a potential therapeutic agent with its low toxicity and anticancer properties. In this study, the anticancer effect of EA on ovarian cancer cell lines and normal ovarian surface epithelial cells (OSE) was evaluated. The antiproliferative effect of EA was evaluated by xCELLigence Real-Time Cell analysis, colony formation assay, and acridine orange and DAPI staining methods. Genotoxicity analysis was performed by comet assay. The effect of EA on cell migration was analyzed by wound healing assay. The potential of EA to induce apoptosis was also determined by evaluating the changes in gene and protein expression levels by qRT-PCR and Western blot analysis, respectively. EA was found to be a promising potential therapeutic agent for ovarian cancer without showing significant cytotoxic effect on normal cells. Furthermore, EA decreased the ability of ovarian cancer cells for migration, increased the rate of apoptosis by inhibiting BIRC5 and activating CASP3, triggered cell cycle arrest in the G2/M phase, and caused a decrease in mitochondrial membrane potential and genotoxic effects. The results have shown that EA could be an effective candidate molecule for ovarian cancer treatment.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMembrane Potential, MitochondrialMolecular StructureStructure-Activity RelationshipAntineoplastic Agentsanticancerapoptosisevernic acidovarian cancer

Identifiers

PMID40405479
PMCPMC12099196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.